James F. Howard

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Spinal cord infarction

William P. Cheshire, César Santos, E W Massey et al. · Neurology · 1996 · 443 citations

Medicine, Neurology, Neurosurgery +13

Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data

Eric I. Benchimol, Astrid Guttmann, AN Griffiths et al. · Gut · 2009 · 412 citations

Public Health, Child Health, Pediatrics +15

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 288 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14